EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A rebrand for proteasome inhibition in solid tumors via continuous hepatic artery infusion

Carolina M Larrain, Jack H Victory, Priyanka P Desai, Lindsay R Friedman, Hannah Stepp, Rachel Ashe, Kirsten Remmert, Surajit Sinha, Emily C Smith, Nicole Russell, Tracey Pu, Alyssa V Eade und 7 weitere

JCI Insight · 2025

DOI: 10.1172/jci.insight.199200 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCI Insight, 2025. Verfasst von Carolina M Larrain und 18 weiteren Autor:innen. Beteiligte Einrichtung: Surgical Oncology Program. Hauptthemen laut MEDLINE: Proteasome Inhibitors, Oligopeptides, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This research was supported by the Intramural Research Program of the National Institutes of Health (NIH), the S. Ritterbush Fund, and the MIT Center for Preci….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeting tumors with proteosome inhibitors has demonstrated antitumor activity and has been successfully translated to the clinic for patients with multiple myeloma. However, in patients with solid tumors, treatment with proteosome inhibitors as single agents has consistently failed to yield meaningful responses. In our study, we investigate the potential of hepatic artery infusion pump delivery of carfilzomib, to continuously direct a large dose to the tumor with least hepatic toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proteasome InhibitorsOligopeptidesNeoplasmsAntineoplastic AgentsHepatic ArteryHumansInfusions, Intra-ArterialAnimalsMiceMaleFemaleCell Line, TumorXenograft Model Antitumor Assays

Stichwörter der Autor:innen

Colorectal cancerHepatologyOncology

Substanzen

Proteasome InhibitorsOligopeptidescarfilzomibAntineoplastic Agents

Autor:innen und Institutionen

  • Surgical Oncology Program.
  • Genitourinary Malignancies Branch, and.
  • Laboratory of Pathology, National Cancer Institute, NIH, Bethesda, Maryland, USA.

Förderung

  • This research was supported by the Intramural Research Program of the National Institutes of Health (NIH), the S. Ritterbush Fund, and the MIT Center for Preci…

Zitieren

APA

Larrain, C. M., Victory, J. H., Desai, P. P., Friedman, L. R., Stepp, H., Ashe, R., Remmert, K., Sinha, S., Smith, E. C., Russell, N., Pu, T., Eade, A. V., Burke, J. F., Ho, J., Yaffe, M. B., Kleiner, D. E., Schmidt, K., Figg, W. D., & Hernandez, J. M. (2025). A rebrand for proteasome inhibition in solid tumors via continuous hepatic artery infusion. JCI Insight. https://doi.org/10.1172/jci.insight.199200

Vancouver

Larrain CM, Victory JH, Desai PP, Friedman LR, Stepp H, Ashe R, et al. A rebrand for proteasome inhibition in solid tumors via continuous hepatic artery infusion. JCI Insight. 2025. doi:10.1172/jci.insight.199200

BibTeX
@article{Larrain2025,
  author = {Larrain, Carolina M and Victory, Jack H and Desai, Priyanka P and Friedman, Lindsay R and Stepp, Hannah and Ashe, Rachel and Remmert, Kirsten and Sinha, Surajit and Smith, Emily C and Russell, Nicole and Pu, Tracey and Eade, Alyssa V and Burke, Justine F and Ho, Jason and Yaffe, Michael B and Kleiner, David E and Schmidt, Keith and Figg, William D and Hernandez, Jonathan M},
  title = {A rebrand for proteasome inhibition in solid tumors via continuous hepatic artery infusion},
  journal = {JCI Insight},
  year = {2025},
  doi = {10.1172/jci.insight.199200}
}
Kostenlos starten →